Free Expedited Shipping On Orders Over $199

GLP-2 TZ – Tirzepatide (15MG) – Average Weight 16.25MG

Price range: $65.00 through $520.00

Third Party COA 

Lab: SideChain Analytics

Date: October 21, 2026

Purity: 99.8%

Mass: 16.25 MG

View COA

For in vitro laboratory research use only. Not for human consumption.

Description

GLP-2 TZ

Dual GIP and GLP-1 Receptor Agonist

GLP-2 TZ is a synthetic peptide-based compound studied for its activity at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its dual-receptor mechanism has made it a significant subject of scientific research into metabolic regulation, glucose homeostasis, and energy balance.

Research Overview

GLP-2 TZ has been investigated for its effects on incretin receptor signaling, glucose-dependent insulin secretion, and gastrointestinal processes involved in metabolic regulation. Research has also examined its influence on appetite-related signaling and body-weight regulation in clinical settings.

Compound Information

  • Classification: Dual GIP/GLP-1 receptor agonist
  • Research focus: Incretin signaling and metabolic physiology
  • Intended designation: Research Use Only (RUO)

Third Party COA 

Lab: SideChain Analytics

Date: October 21, 2026

Purity: 99.8%

Mass: 16.25 MG

View COA

 

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.

 

Additional information

Quantity

Single, 3 Pack, 5 Pack, 10 Pack

Reviews

There are no reviews yet.

Be the first to review “GLP-2 TZ – Tirzepatide (15MG) – Average Weight 16.25MG”

Your email address will not be published. Required fields are marked *